Cash Expected to Fund Operations into Q2 2018...

Newly Reported Bleeding Profile Shows Reduction in Unscheduled Bleeding/Spotting Days...

PRINCETON, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company today announced that data from its Phase 3 SECURE study will be presented at the interactive ePoster session during the 2017 Annual Clinical and Scientific Meeting of the American...

PRINCETON, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company announced today that a presentation entitled " An Update on Hormonal Contraception and The Changing U.S. Population " will be presented by Co-Principal Investigator of the SECURE...

Confirms Plans to Re-submit New Drug Application for Twirla® by the end of the Second Quarter of 2017...

PRINCETON, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, announced a poster presentation of data from the SECURE Phase 3 clinical trial for its lead product candidate, Twirla ® , (ethinyl estradiol and levonorgestrel transdermal...

Current Business Plan Expected to Extend Cash Position and Fund Operations into Q2 2018...

Presentation Scheduled on Monday, March 13, 2017 at 4:30 PM Pacific Time...

Presentation Scheduled on February 23, 2017 at 10:00 AM ET...

Presentation Scheduled on Monday, February 13th, 2017 at 11:00 am ET...